Table 2 Anticitrullinated peptide autoantibodies in women and risk of future rheumatoid arthritis in the Nurses’ Health Study and the Nurses’ Health Study II a
ACPA target | Positive cases (N = 192) | Positive controls (N = 567) | Unadjusted RR (95% CI) | P value | Adjusted RR (95% CI) | P value |
|---|---|---|---|---|---|---|
Any ACPA | 48 | 38 | 4.9 (3.0 to 7.8) | <0.0001 | 4.9 (2.9 to 8.2) | <0.0001 |
Biglycan | 10 | 5 | 6.0 (2.1 to 17.5) | 0.001 | 4.7 (1.6 to 14.2) | 0.006 |
Clusterin | 25 | 7 | 12.2 (5.0 to 29.8) | <0.0001 | 11.7 (4.7 to 26.3) | <0.0001 |
Enolase | 5 | 3 | 5.0 (1.2 to 20.9) | 0.03 | 5.8 (1.3 to 27.1) | 0.02 |
Fibrinogen | 37 | 22 | 6.3 (3.5 to 11.4) | <0.0001 | 5.9 (3.2 to 11.0) | <0.0001 |
Histone 2A | 13 | 8 | 4.9 (2.0 to 11.8) | <0.001 | 5.3 (2.1 to 13.2) | <0.001 |
Histone 2B | 18 | 8 | 7.3 (3.1 to 17.6) | <0.0001 | 7.0 (2.8 to 17.2) | <0.0001 |
Vimentin | 28 | 11 | 9.8 (4.5 to 21.6) | <0.0001 | 9.7 (4.3 to 21.8) | <0.0001 |